Genentech announces Bill Anderson as new CEO

pharmafile | December 16, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bill Anderson, Genentech, Roche 

Genentech, the biotech subsidiary of Roche, has announced that Genentech veteran, Ian Clark, will retire as CEO on 1 January. Ian Clark performed his role as the CEO of Genentech for the last 15 years, bringing through 15 new drugs in the process and dealing with the after-effects of Roche’s buyout of the company.

Bill Anderson takes the positon of CEO after having worked within Genentech for the last decade. He has held a number of positions within the company and will switch to the role from his current position as North American commercial chief, a position he has held since July. Prior to this, he held the position of global product strategy chief for Roche and headed Genentech’s bio-oncology business.

“Bill is an outstanding leader with a deep understanding of the company and proven expertise in bringing important medicines to people with serious diseases,” said Daniel O’Day, CEO of Roche’s pharmaceuticals division.

Related Content


Genentech and NVIDIA enter AI research collaboration

Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA …

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …

Roche announces acquisition of Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …

Latest content